Physician profile
Eugene Lee
NPI 1023049590
$1,578.67
in general payments reported to CMS, 2019-2025
12 companies · $163 in 2025
The $163 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.77 · 2020: $56.03 · 2021: $453 · 2022: $530 · 2023: $198 · 2024: $132 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $492.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,008.52 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $155.52 | 2019-2023 | Entyvio |
| Nestle Healthcare Nutrition INC. | $129.88 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $44.86 | 2023-2024 | Dificid |
| Janssen Biotech, INC. | $44.28 | 2022-2023 | Simponi, Simponi Aria, Stelara |
| Braintree Laboratories, INC. | $41.50 | 2019-2021 | |
| Pfizer INC. | $40.00 | 2024 | |
| Genzyme Corporation | $28.79 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.20 | 2021 | |
| Intercept Pharmaceuticals, INC. | $21.26 | 2022 | |
| Qol Medical, LLC | $20.35 | 2023 | Sucraid |
| Ferring Pharmaceuticals INC. | $19.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.